Search results
IN8bio (NASDAQ:INAB) PT Lowered to $12.50 at HC Wainwright
ETF DAILY NEWS· 19 hours agoIN8bio (NASDAQ:INAB – Free Report) had its price target decreased by HC Wainwright from $14.00 to $12.50 in a report released on Monday, Benzinga reports. HC Wainwright currently has a
Alphabet Bought Up Two Slumping Stocks
Barrons.com· 5 days agoThe stock is down nearly 20% so far in the second quarter. The biotech, which focuses on gene-editing therapies, received gross proceeds of $161 million...
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
Investor's Business Daily· 2 days agoOver 100 years of market history reveals that the stocks that go on to make the biggest gains tend...
Arora Ashish Sells 129,186 Shares of Cricut, Inc. (NASDAQ:CRCT) Stock
ETF DAILY NEWS· 20 hours agoFollowing the sale, the chief executive officer now directly owns 2,090,420 shares of the company’s ...
Twist Bioscience Co. (NASDAQ:TWST) Given Consensus Rating of “Buy” by Analysts
ETF DAILY NEWS· 7 days agoSix equities research analysts have rated the stock with a buy rating. Evercore ISI lifted their price target on shares of Twist Bioscience from $46.00 ...
Novavax Stock Just Tripled. Is It Too Late to Buy? | The Motley Fool
The Motley Fool· 2 days agoAfter losing more than 90% of its value from a peak back in 2021, Novavax (NVAX -4.30%) stock has...
Cipher Mining (NASDAQ:CIFR) Stock Rating Reaffirmed by Needham & Company LLC
ETF DAILY NEWS· 7 days agoCipher Mining (NASDAQ:CIFR – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a research note issued ...
Fulcrum Therapeutics (NASDAQ:FULC) Raised to Buy at The Goldman Sachs Group
ETF DAILY NEWS· 20 hours agoThe Goldman Sachs Group upgraded shares of Fulcrum Therapeutics (NASDAQ:FULC – Free Report) from a neutral rating to a buy rating in a report issued on Monday, Benzinga reports ...
Amgen Is Working On a Wegovy Competitor -- What It Means for Investors
Motley Fool via Yahoo Finance· 5 days agoAmgen also has several pre-clinical anti-obesity programs it is working on right now. Is the stock a...
Natixis Advisors L.P. Buys 4,941 Shares of Glaukos Co. (NYSE:GKOS)
ETF DAILY NEWS· 4 days ago(NYSE:GKOS – Free Report) by 14.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 38,920 shares of the medical instruments supplier’s stock ...
